{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T13:20:41Z","timestamp":1794835241702,"version":"4.9.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"13","license":[{"start":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T00:00:00Z","timestamp":1783382400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T00:00:00Z","timestamp":1783382400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2026,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Systemic therapy is generally recommended for patients with stage IV lung cancer over primary tumor resection (PTR). Although some randomized trials have shown a survival benefit of PTR in advanced ovarian cancer, breast cancer, and colorectal cancer with peritoneal carcinomatosis, the efficacy of PTR in stage IV lung cancer remains uncertain. This study aimed to determine whether PTR affects the survival of patients with stage IV epidermal growth factor receptor (EGFR)-mutant lung adenocarcinoma (ADC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods<\/jats:title>\n                    <jats:p>We utilized the cancer registry database of Kaohsiung Chang Gung Memorial Hospital, Taiwan. Between 1 January 2018 and 21 December 2022, 652 patients were diagnosed with stage IV EGFR-mutant lung ADC. After exclusion, 400 patients were included, 33 of whom underwent PTR. After propensity score matching, 26 patients who underwent PTR and 78 who did not were selected for the analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Patients who received PTR exhibited better progression-free survival (PFS) (not reached (NR) versus 17.1 months;\n                      <jats:italic>p<\/jats:italic>\n                      = 0.001) and overall survival (OS) (NR versus 38.2 months;\n                      <jats:italic>p<\/jats:italic>\n                      = 0.011) than patients who did not. In the multivariate analysis, lower clinical M stage and PTR were significantly associated with improved PFS and OS. Subgroup analysis of independent factors regarding both PFS and OS that predicted improvement following PTR included male sex, age \u2265 60, never smoked, performance status (PS) = 1, clinical T stage 3\u20134, clinical N stage 0\u20132, and clinical M stage 1a.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In patients with stage IV EGFR-mutant lung ADC and good PS, PTR before progression under first-line TKI treatment may improve survival.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1245\/s10434-026-20063-y","type":"journal-article","created":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T14:22:43Z","timestamp":1783434163000},"page":"11285-11295","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Resection of Primary Lung Tumors in Patients with Stage IV EGFR-Mutant Lung Adenocarcinoma before Progression under First-Line TKI Treatment and Its Impact on Prognosis"],"prefix":"10.1245","volume":"33","author":[{"given":"Yu-Ping","family":"Chang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Mu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meng-Yun","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suey-Haur","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiung-Yu","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chin-Chou","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chien-Ming","family":"Lo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huang-Chih","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hung-Chen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chun-Fu","family":"Chung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hsing-Hua","family":"Lai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kai-Hao","family":"Chuang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kuo-Tung","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"},{"role":"corresponding-author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,7,7]]},"reference":[{"key":"20063_CR1","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1093\/jjco\/hyab107","volume":"51","author":"T Hishida","year":"2021","unstructured":"Hishida T, Masai K, Kaseda K, Asakura K, Asamura H. Debulking surgery for malignant tumors: the current status, evidence and future perspectives. Jpn J Clin Oncol. 2021;51:1349\u201362.","journal-title":"Jpn J Clin Oncol."},{"key":"20063_CR2","doi-asserted-by":"publisher","first-page":"249","DOI":"10.6004\/jnccn.2204.0023","volume":"22","author":"GJ Riely","year":"2024","unstructured":"Riely GJ, Wood DE, Ettinger DS, et al. Non-small cell lung cancer, version 4.2024, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2024;22:249\u201374.","journal-title":"J Natl Compr Canc Netw."},{"key":"20063_CR3","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.lungcan.2017.11.021","volume":"115","author":"CJ Yang","year":"2018","unstructured":"Yang CJ, Gu L, Shah SA, et al. Long-term outcomes of surgical resection for stage IV non-small-cell lung cancer: a national analysis. Lung Cancer. 2018;115:75\u201383.","journal-title":"Lung Cancer."},{"key":"20063_CR4","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1093\/icvts\/ivr036","volume":"14","author":"D Kawano","year":"2012","unstructured":"Kawano D, Takeo S, Katsura M, Tsukamoto S, Masuyama E, Nakaji Y. Surgical treatment of stage IV non-small cell lung cancer. Interact Cardiovasc Thorac Surg. 2012;14:167\u201370.","journal-title":"Interact Cardiovasc Thorac Surg."},{"key":"20063_CR5","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/s12890-023-02411-w","volume":"23","author":"J Ren","year":"2023","unstructured":"Ren J, Ren J, Wang K, Tan Q. The consideration of surgery on primary lesion of advanced non-small cell lung cancer. BMC Pulm Med. 2023;23:118.","journal-title":"BMC Pulm Med."},{"key":"20063_CR6","doi-asserted-by":"publisher","first-page":"22560","DOI":"10.1038\/s41598-022-22957-9","volume":"12","author":"YY Chen","year":"2022","unstructured":"Chen YY, Su PL, Huang WL, et al. The surgical resection of the primary tumor increases survival in patients with EGFR-mutant advanced non-small cell lung cancer: a tertiary center cohort study. Sci Rep. 2022;12:22560.","journal-title":"Sci Rep."},{"key":"20063_CR7","doi-asserted-by":"publisher","first-page":"4873","DOI":"10.1245\/s10434-022-11483-7","volume":"29","author":"SW Kuo","year":"2022","unstructured":"Kuo SW, Chen PH, Lu TP, et al. Primary tumor resection for Stage IV non-small-cell lung cancer without progression after first-line epidermal growth factor receptor-tyrosine kinase inhibitor treatment: a retrospective case\u2013control study. Ann Surg Oncol. 2022;29:4873\u201384.","journal-title":"Ann Surg Oncol."},{"key":"20063_CR8","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1159\/000509664","volume":"99","author":"JS Tseng","year":"2021","unstructured":"Tseng JS, Hsu KH, Zheng ZR, et al. Primary tumor resection is associated with a better outcome among advanced EGFR-mutant lung adenocarcinoma patients receiving EGFR-TKI treatment. Oncology. 2021;99:32\u201340.","journal-title":"Oncology."},{"key":"20063_CR9","first-page":"156","volume":"4","author":"T Kohno","year":"2015","unstructured":"Kohno T, Nakaoku T, Tsuta K, et al. Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer. Transl Lung Cancer Res. 2015;4:156\u201364.","journal-title":"Transl Lung Cancer Res."},{"key":"20063_CR10","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1056\/NEJMoa2304594","volume":"389","author":"M Tsuboi","year":"2023","unstructured":"Tsuboi M, Herbst RS, John T, et al. Overall survival with osimertinib in resected EGFR-mutated NSCLC. N Engl J Med. 2023;389:137\u201347.","journal-title":"N Engl J Med."},{"key":"20063_CR11","doi-asserted-by":"publisher","first-page":"2875","DOI":"10.1200\/JCO-25-00883","volume":"43","author":"J He","year":"2025","unstructured":"He J, Tsuboi M, Weder W, et al. Neoadjuvant osimertinib for resectable EGFR-mutated non-small cell lung cancer. J Clin Oncol. 2025;43:2875\u201387.","journal-title":"J Clin Oncol."},{"key":"20063_CR12","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1200\/JCO.19.00201","volume":"37","author":"DR Gomez","year":"2019","unstructured":"Gomez DR, Tang C, Zhang J, et al. Local consolidative therapy vs. maintenance therapy or observation for patients with oligometastatic non\u2013small-cell lung cancer: long-term results of a multi-institutional, Phase II, randomized study. J Clin Oncol. 2019;37:1558\u201365.","journal-title":"J Clin Oncol."},{"key":"20063_CR13","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.3501","volume":"4","author":"P Iyengar","year":"2018","unstructured":"Iyengar P, Wardak Z, Gerber DE, et al. Consolidative radiotherapy for limited metastatic non\u2013small-cell lung cancer: a phase 2 randomized clinical trial. JAMA Oncol. 2018;4:e173501.","journal-title":"JAMA Oncol."},{"key":"20063_CR14","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","volume":"5","author":"MM Oken","year":"1982","unstructured":"Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5:649\u201355.","journal-title":"Am J Clin Oncol."},{"key":"20063_CR15","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.lungcan.2020.08.010","volume":"148","author":"K Suda","year":"2020","unstructured":"Suda K, Murakami I, Obata K, et al. Spatial heterogeneity of acquired resistance mechanisms to 1st\/2nd generation EGFR tyrosine kinase inhibitors in lung cancer. Lung Cancer. 2020;148:100\u20134.","journal-title":"Lung Cancer."},{"key":"20063_CR16","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1080\/02841860802662722","volume":"48","author":"KE Rusthoven","year":"2009","unstructured":"Rusthoven KE, Hammerman SF, Kavanagh BD, Birtwhistle MJ, Stares M, Camidge DR. Is there a role for consolidative stereotactic body radiation therapy following first-line systemic therapy for metastatic lung cancer? A patterns-of-failure analysis. Acta Oncol. 2009;48:578\u201383.","journal-title":"Acta Oncol."},{"key":"20063_CR17","doi-asserted-by":"publisher","first-page":"3409","DOI":"10.21037\/tlcr-21-58","volume":"10","author":"L Berzenji","year":"2021","unstructured":"Berzenji L, Debaenst S, Hendriks JMH, Yogeswaran SK, Lauwers P, Van Schil PE. The role of the surgeon in the management of oligometastatic non-small cell lung cancer: a literature review. Transl Lung Cancer Res. 2021;10:3409\u201319.","journal-title":"Transl Lung Cancer Res."},{"key":"20063_CR18","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.lungcan.2018.11.012","volume":"129","author":"Z Sun","year":"2019","unstructured":"Sun Z, Sui X, Yang F, Wang J. Effects of primary tumor resection on the survival of patients with stage IV extrathoracic metastatic non-small cell lung cancer: a population-based study. Lung Cancer. 2019;129:98\u2013106.","journal-title":"Lung Cancer."},{"key":"20063_CR19","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/j.ejca.2020.12.002","volume":"144","author":"J Jia","year":"2021","unstructured":"Jia J, Guo B, Yang Z, et al. Outcomes of local thoracic surgery in patients with stage IV non-small-cell lung cancer: a SEER-based analysis. Eur J Cancer. 2021;144:326\u201340.","journal-title":"Eur J Cancer."},{"key":"20063_CR20","doi-asserted-by":"publisher","first-page":"22445","DOI":"10.1038\/s41598-024-73389-6","volume":"14","author":"T Xie","year":"2024","unstructured":"Xie T, Qiu BM, Luo J, et al. Distant metastasis patterns among lung cancer subtypes and impact of primary tumor resection on survival in metastatic lung cancer using SEER database. Sci Rep. 2024;14:22445.","journal-title":"Sci Rep."},{"key":"20063_CR21","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1055\/s-0035-1564928","volume":"66","author":"JK Yun","year":"2018","unstructured":"Yun JK, Kim MA, Choi CM, et al. Surgical outcomes after pulmonary resection for non\u2013small cell lung cancer with localized pleural seeding first detected during surgery. Thorac Cardiovasc Surg. 2018;66:142\u20139.","journal-title":"Thorac Cardiovasc Surg."},{"key":"20063_CR22","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1016\/j.jtcvs.2017.09.162","volume":"155","author":"C Li","year":"2018","unstructured":"Li C, Kuo SW, Hsu HH, Lin MW, Chen JS. Lung adenocarcinoma with intraoperatively diagnosed pleural seeding: Is main tumor resection beneficial for prognosis? J Thorac Cardiovasc Surg. 2018;155:1238-1249.e1.","journal-title":"J Thorac Cardiovasc Surg."},{"key":"20063_CR23","doi-asserted-by":"publisher","first-page":"2715","DOI":"10.1093\/annonc\/mdx404","volume":"28","author":"C Leduc","year":"2017","unstructured":"Leduc C, Merlio JP, Besse B, et al. Clinical and molecular characteristics of non-small-cell lung cancer (NSCLC) harboring EGFR mutation: results of the nationwide French Cooperative Thoracic Intergroup (IFCT) program. Ann Oncol. 2017;28:2715\u201324.","journal-title":"Ann Oncol."},{"issue":"Supplement 1","key":"20063_CR24","first-page":"S162","volume":"6","author":"D Spyratos","year":"2014","unstructured":"Spyratos D, Zarogoulidis P, Porpodis K, et al. Preoperative evaluation for lung cancer resection. J Thorac Dis. 2014;6(Supplement 1):S162-166.","journal-title":"J Thorac Dis."},{"key":"20063_CR25","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/j.lungcan.2015.09.024","volume":"90","author":"JS Tseng","year":"2015","unstructured":"Tseng JS, Wang CL, Yang TY, et al. Divergent epidermal growth factor receptor mutation patterns between smokers and non-smokers with lung adenocarcinoma. Lung Cancer. 2015;90:472\u20136.","journal-title":"Lung Cancer."},{"key":"20063_CR26","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.lungcan.2014.01.022","volume":"84","author":"MH Kim","year":"2014","unstructured":"Kim MH, Kim HR, Cho BC, et al. Impact of cigarette smoking on response to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors in lung adenocarcinoma with activating EGFR mutations. Lung Cancer. 2014;84:196\u2013202.","journal-title":"Lung Cancer."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-20063-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-026-20063-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-20063-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T12:35:29Z","timestamp":1794832529000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-026-20063-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,7]]},"references-count":26,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["20063"],"URL":"https:\/\/doi.org\/10.1245\/s10434-026-20063-y","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,7]]},"assertion":[{"value":"5 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no competing interests.","order":1,"name":"Ethics","label":"Disclosure","group":{"name":"EthicsHeading","label":"Ethics"}}]}}